NEWARK, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three upcoming investor conferences: the Piper Jaffray 30th Annual Healthcare Conference, the Evercore ISI HealthCONx Conference, and the BMO Prescriptions for Success Conference.
|Piper Jaffray 30th Annual Healthcare Conference|
|Date:||Tuesday, November 27|
|Time:||12:00pm Eastern Time|
|Location:||Lotte New York Palace Hotel|
|Evercore ISI HealthCONx Conference|
|Date:||Wednesday, November 28|
|Time:||9:05am Eastern Time|
|Location:||Boston Harbor Hotel|
|BMO Prescriptions for Success Conference|
|Date:||Wednesday, December 12|
|Time:||11:40am Eastern Time|
|Location:||Mandarin Oriental NYC|
To access a live webcast and subsequent archived recording of each presentation, please visit the “Events” section on the CymaBay website at http://ir.cymabay.com/events.
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently conducting a Phase 3 study of seladelpar for PBC and a Phase 2b study of seladelpar for NASH.
For additional information about CymaBay visit www.cymabay.com.
LifeSci Advisors, LLC